Environmental and genetic susceptibility to MLL-defined infant leukemia

Journal of the National Cancer Institute - Monographs

Volumn , Issue 39, 2008, Pages 83-86

  Ross, Julie A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; BIOFLAVONOID; CIPROFLOXACIN; DIPYRONE; EPIPODOPHYLLOTOXIN DERIVATIVE; ESTROGEN DERIVATIVE; ETOPOSIDE; FOLIC ACID; GYRASE INHIBITOR; LAXATIVE; METRONIDAZOLE; MIXED LINEAGE LEUKEMIA PROTEIN; NALIDIXIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; NOVOBIOCIN; PHYTOESTROGEN; PODOPHYLLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD PLACENTA BARRIER; CANCER RISK; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INFANT; LEUKEMIA; MATERNAL NUTRITION; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL;

ENVIRONMENT; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 52149104281     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgn007     Document Type: Conference Paper

References (40)

1. Ries LAG, Eisner MP, Kosary CL, et al. (eds). SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
2. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature. 1993;363(6427): 358-360.
3. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identifica of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci USA. 1997;94(25):13950-13954.
4. Parkin DM, Kramarova E, Draper G, et al. International Incidence of Childhood Cancer, Vol. II. Carey, NC: International Agency for Research on Cancer;1998.
5. Chessells JM. Leukaemia in the young child. Br J Cancer Suppl., 1992;18: S54-S57.
6. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia. 1995;9(5):762-769.
7. Ries LA, Smith MA, Gurney JG, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: National Cancer Institute, SEER Program;1999.
8. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood. 2006;108(2):441-451.
9. Pui CH, Ribeiro RC, Campana D, et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia. 1996;10(6):952-956.
10. Ernst P, Wang J, Korsmeyer SJ. The role of MLL in hematopoiesis and leukemia. Curr Opin Hematol. 2002;9(4):282-287.
11. Popovic R, Zeleznik-Le NJ. MLL: How complex does it get? J Cell Biochem. 2005;95(4):234-242.
12. Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood. 1993; 82(2):544-546.
13. Sorensen PH, Chen CS, Smith FO, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest. 1994;93(1):429-437.
14. Kumar L. Epipodophyllotoxins and secondary leukaemia. Lancet. 1993;342(8875):819-820.
15. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Eng J Med. 1991;325(24):1682-1687.
16. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br J Haematol. 2001;114(3):539-543.
17. Gewirtz DA. Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors? Biochem Pharmacol. 1991;42(12): 2253-2258.
18. Ross JA, Potter JD, Robison LL. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J Natl Cancer Inst. 1994;86(22):1678-1680.
19. Austin CA, Patel S, Ono K, Nakane H, Fisher LM. Site-specific DNA cleavage by mammalian DNA topoisomerase II induced by novel flavone and catechin derivatives. Biochem J. 1992;282(Pt 3):883-889.
20. Yamashita Y, Kawada S, Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol. 1990;39(4):737-744.
21. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA. 2000;97(9):4790-4795.
22. Ross JA, Potter JD, Reaman GH, Pendergrass TW, Robison LL. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group. Cancer Causes Control. 1996;7(6):581-590.
23. Constantinou A, Stoner GD, Mehta R, Rao K, Runyan C, Moon R. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro. Nutr Cancer. 1995;23(2):121-130.
24. Spector LG, Xie Y, Robison LL, et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev. 2005;14(3):651-655.
25. Ross JA. Dietary flavonoids and the MLL gene: A pathway to infant leukemia? [comment]. Proc Natl Acad Sci USA. 2000;97(9):4411-4413.
26. Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002;22:19-34.
27. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett. 1997;114(1-2):139-140.
28. Adlercreutz H, Yamada T, Wahala K, Watanabe S. Maternal and neonatal phytoestrogens in Japanese women during birth. Am J Obstet Gynecol. 1999;180(3 Pt 1):737-743.
29. Todaka E, Sakurai K, Fukata H, et al. Fetal exposure to phytoestrogens - the difference in phytoestrogen status between mother and fetus. Environ Res. 2005;99(2):195-203.
30. Armstrong SA, Golub TR, Korsmeyer SJ. MLL-rearranged leukemias: Insights from gene expression profiling. Semin Hematol. 2003;40(4): 268-273.
31. Strick R, Strissel PL, Borgers S, Smith SL, Rowley JD. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA. 2000;97(9):4790-4795.
32. Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001; 61(6):2542-2546.
33. Locksmith GJ, Duff P. Preventing neural tube defects: The importance of periconceptional folic acid supplements. Obstet Gynecol. 1998;91(6): 1027-1034.
34. Ross JA. Dietary flavonoids and the MLL gene: a pathway to infant leukemia? Proc Natl Acad Sci USA. 2000;97(9):4411-4413.
35. Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. A lack of a functional NAD(P)H: Quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res. 1999;59(16):4095-4099.
36. Smith MT, Wang Y, Skibola CF, et al. Low NAD(P)H: Quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood. 2002;100(13):4590-4593.
37. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexander FE, Greaves MF. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defi ned subtypes of childhood acute leukemia. Proc Natl Acad Sci USA. 2001;98(7):4004-4009.
38. Labuda D, Krajinovic M, Sabbagh A, Infante-Rivard C, Sinnett D. Parental genotypes in the risk of a complex disease. Am J Hum Genetics. 2002;71(1):193-197.
39. Chen W, Li Q, Hudson WA, Kumar A, Kirchhof N, Kersey JH. A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood. 2006;108(2):669-677.
40. Kong CT, Sham MH, So CW, Cheah KS, Chen SJ, Chan LC. The Mll-Een knockin fusion gene enhances proliferation of myeloid progenitors derived from mouse embryonic stem cells and causes myeloid leukaemia in chimeric mice. Leukemia. 2006;20(10):1829-1839.